Gut cells in people with IBD stay primed to die even in remission, which may explain flare-ups

People with inflammatory bowel disease can go months or years without symptoms and still relapse, and until now there has been little biological explanation for why the disease keeps returning. Researchers at the Walter and Eliza Hall Institute in Melbourne report that the cells lining the gut stay primed to die even when patients feel well, a persistent signal that tracked with who went on to relapse.

The study appeared in the journal Science, and WEHI announced it on August 28. Later reposts, including one on ScienceDaily in mid-September, gave it a second life, but the underlying work dates to late August.

Nine hundred biopsies and a smoldering defect

The research team, which included clinicians from the Royal Melbourne Hospital, “collected around 900 biopsies from 80 individuals with and without IBD,” according to the institute’s announcement. The paper is titled “A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease” and carries the identifier 10.1126/science.aeh7112.

The word the scientists use for what they found is “smoldering.” Dr. Andre Samson, one of the lead researchers, said that in the patient samples the intestinal cells were primed to die. “Even in patients with essentially no symptoms, there’s still this persistent problem sitting there,” he said. Samson also noted a plain clinical fact behind the work: once diagnosed, IBD does not go away, and even people who are symptom-free on current treatments face a real likelihood of a flare or relapse.

Two forms of cell death, one axis

Necroptosis and apoptosis are two programmed ways for a cell to die. Necroptosis is an inflammatory form that spills a cell’s contents and can provoke more inflammation nearby, while apoptosis is a more orderly self-dismantling. The paper’s title describes a signaling axis running from the first toward the second, and a 2024 preprint version of the work reported that necroptotic activation appears even in histologically normal tissue and that the signaling persists in people receiving advanced therapies.

The same preprint used three-dimensional intestinal organoids, mini-guts grown from patient cells, to show that the inflammatory signals interferon-gamma and TNF work together to kill gut lining cells. Dr. Jiyi Pang, who worked on the organoid experiments, said the team used them “and by working alongside a diverse team of researchers and clinicians” to uncover “the inflammatory signals responsible for this cell death response.”

Higher signaling, more relapses

The link to flare-ups comes from follow-up. The WEHI team says it “followed these patients for more than two years and found that people with higher levels of intestinal cell death signalling were also more likely to relapse.” That is an association in a cohort of 80 people, not proof that the cell-death signal causes relapse, which is why the researchers present it as a possible explanation for flare-ups rather than a proven one.

Professor James Murphy, whose laboratory helped lead the work, said the group looked at “gut tissue that doesn’t have clear signs of active disease” and found the “molecular defect happening very early in disease progression.” That timing supports a reading in which cell death is not merely damage left behind by inflammation but part of what drives the disease, a point SciTechDaily’s write-up also draws from the team’s comments.

The design matters for how far the result can be pushed. Because the cohort included people with and without IBD, the researchers could compare diseased and healthy tissue directly, and because biopsies were paired with organoids, they could move from observing that cell-death genes were switched on to testing which inflammatory signals switched them on. The collaborators came from the Royal Melbourne Hospital, the University of Melbourne, Monash University and the Hudson Institute, among others. What the design cannot do is show that intervening on the axis would prevent a single relapse.

What this does and does not yet offer patients

Nothing in the study is a test a gastroenterologist can order today, and no drug aimed at this axis is described as being in patients’ hands. The WEHI release is explicit: “While the findings may not immediately translate into a new diagnostic test or treatment, they provide a strong foundation for future work.” The ScienceDaily repost carries the same caution.

The longer-term hope is monitoring and matching. The EurekAlert version of the release quotes Dr. Aysha Al-Ani on how more sensitive molecular detection may help keep patients in deep remission for longer, by showing which markers respond to which therapies. The researchers say the findings could support earlier flare prediction and treatment selected by the biology of an individual’s disease rather than by symptoms alone.

The study was backed by the Kenneth Rainin Foundation, Australia’s National Health and Medical Research Council, the Australian Research Council, Crohn’s and Colitis Australia and several other funders. Whether the cell-death signal can be measured reliably enough in routine biopsies, and whether treating it changes relapse rates, are the questions the 80-person cohort cannot answer by itself.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview